A. E. Eskazan, "Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?," CANCER , vol.124, no.21, pp.4260-4261, 2018
Eskazan, A. E. 2018. Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?. CANCER , vol.124, no.21 , 4260-4261.
Eskazan, A. E., (2018). Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?. CANCER , vol.124, no.21, 4260-4261.
Eskazan, Ahmet. "Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?," CANCER , vol.124, no.21, 4260-4261, 2018
Eskazan, Ahmet E. . "Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?." CANCER , vol.124, no.21, pp.4260-4261, 2018
Eskazan, A. E. (2018) . "Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?." CANCER , vol.124, no.21, pp.4260-4261.
@article{article, author={Ahmet Emre EŞKAZAN}, title={Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?}, journal={CANCER}, year=2018, pages={4260-4261} }